| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |